-
US jet downs Iran drone but talks still on course
-
UK police launching criminal probe into ex-envoy Mandelson
-
US-Iran talks 'still scheduled' after drone shot down: White House
-
Chomsky sympathized with Epstein over 'horrible' press treatment
-
French prosecutors stick to demand for five-year ban for Le Pen
-
Russia's economic growth slowed to 1% in 2025: Putin
-
Bethell spins England to 3-0 sweep over Sri Lanka in World Cup warm-up
-
Nagelsmann backs Ter Stegen for World Cup despite 'cruel' injury
-
Homage or propaganda? Carnival parade stars Brazil's Lula
-
EU must be 'less naive' in COP climate talks: French ministry
-
Colombia's Petro meets Trump after months of tensions
-
Air India inspects Boeing 787 fuel switches after grounding
-
US envoy evokes transition to 'democratic' Venezuela
-
Syria govt forces enter Qamishli under agreement with Kurds
-
Vonn says will defy injury and hunt for medals at Olympics
-
WHO wants $1 bn for world's worst health crises in 2026
-
France summons Musk, raids X offices as deepfake backlash grows
-
Four out of every 10 cancer cases are preventable: WHO
-
Sex was consensual, Norway crown princess's son tells rape trial
-
Sacked UK envoy Mandelson quits parliament over Epstein ties
-
US House to vote Tuesday to end partial government shutdown
-
Eswatini minister slammed for reported threat to expel LGBTQ pupils
-
Pfizer shares drop on quarterly loss
-
Norway's Kilde withdraws from Winter Olympics
-
Vonn says 'confident' can compete at Olympics despite ruptured ACL
-
Germany acquires power grid stake from Dutch operator
-
France summons Musk for questioning as X deepfake backlash grows
-
Finland building icebreakers for US amid Arctic tensions
-
Petro extradites drug lord hours before White House visit
-
Disney names theme parks chief Josh D'Amaro as next CEO
-
Disney names theme parks boss chief Josh D'Amaro as next CEO
-
Macron says work under way to resume contact with Putin
-
Prosecutors to request bans from office in Le Pen appeal trial
-
Tearful Gazans finally reunite after limited Rafah reopening
-
Iran president confirms talks with US after Trump's threats
-
Spanish skater allowed to use Minions music at Olympics
-
Fire 'under control' at bazaar in western Tehran
-
Howe trusts Tonali will not follow Isak lead out of Newcastle
-
Vonn to provide injury update as Milan-Cortina Olympics near
-
France summons Musk for 'voluntary interview', raids X offices
-
Stocks mostly climb as gold recovers
-
US judge to hear request for 'immediate takedown' of Epstein files
-
Russia resumes large-scale strikes on Ukraine in glacial temperatures
-
Fit-again France captain Dupont partners Jalibert against Ireland
-
French summons Musk for 'voluntary interview' as authorities raid X offices
-
IOC chief Coventry calls for focus on sport, not politics
-
McNeil's partner hits out at 'brutal' football industry after Palace move collapses
-
Proud moment as Prendergast brothers picked to start for Ireland
-
Germany has highest share of older workers in EU
-
Teen swims four hours to save family lost at sea off Australia
Moderna to Host Investor Event - Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website
Webcast: investors.modernatx.com.
A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
N.Mitchell--AT